Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 5/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6249101 | 0.82 | ALKBH1 (0.41) | ADORA2AADORA1POLBLMNAL3MBTL1 | |
| SCHEMBL27497366 | 0.82 | ADORA2A (0.38) | ADORA2AADORA1POLBLMNAL3MBTL1 | |
| SCHEMBL15307202 | 0.82 | LMNA (0.41) | ADORA2AADORA1POLBLMNAL3MBTL1 | |
| SCHEMBL29002489 | 0.79 | ADORA2A (0.42) | ADORA2AADORA1L3MBTL1PARP1PARP2 | |
| SCHEMBL174293 | 0.78 | ADORA2A (0.45) | ADORA2AADORA1L3MBTL1GAA | |
| SCHEMBL1224892 | 0.78 | GAA (0.50) | ADORA2AADORA1POLBNNMTGAA | |
| SCHEMBL1833232 | 0.78 | ADORA2A (0.49) | ADORA2AADORA1LMNAL3MBTL1IRAK4 | |
| SCHEMBL7979529 | 0.77 | GAA (0.46) | ADORA2APOLBLMNAL3MBTL1TSHR | |
| SCHEMBL15307174 | 0.77 | ALDH1A1 (0.39) | ADORA2AADORA1POLBLMNAMGLL | |
| SCHEMBL20524576 | 0.77 | GAA (0.39) | ADORA2AADORA1POLBIRAK4NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025119372-A2 | MRGPRX2 ANTAGONIST AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-06-12 | — | — | WO | disclosed |
| CN-120118069-A | MRGPRX2 antagonists and uses | 武汉人福创新药物研发中心有限公司 | 2025-06-10 | — | — | CN | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-101291584-A | Herbicide composition | NISSAN CHEMICAL IND LTD (JP) | 2008-10-22 | — | — | CN | disclosed |
| EP-0537423-B1 | N-pyrazolyl-1,2,4-triazolo(1,5-c)pyrimidine-2-sulfonamide herbicides | DOWELANCO (US) | 1997-10-08 | — | — | EP | disclosed |
| CN-1033806-C | Herbicidal composition | DOWELANCO (US) | 1997-01-15 | — | — | CN | disclosed |
| CN-1134223-A | Method for controling needless plant | DOWELANCO (US) | 1996-10-30 | — | — | CN | disclosed |
| EP-0537423-A1 | N-pyrazolyl-1,2,4-triazolo(1,5-c)pyrimidine-2-sulfonamide herbicides | DowElanco (US) | 1993-04-21 | — | — | EP | disclosed |
| US-5201938-A | N-pyrazolyl-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamide herbicides | DOWELANCO (US) | 1993-04-13 | — | — | US | disclosed |
| CN-1068824-A | N-pyrazolyl-1, 2, 4-triazolo [1, 5-c ] pyrimidine-2-sulfonamides as herbicides | DOWELANCO (US) | 1993-02-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | ADORA2A 2714/4885ADORA1 3747/4885ADRA1D 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.